Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).

Autor: Dhanasekaran R; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA., Gabay-Ryan M; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA., Baylot V; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA., Lai I; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA., Mosley A; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA., Huang X; Regulus Therapeutics, San Diego, CA, USA., Zabludoff S; Regulus Therapeutics, San Diego, CA, USA., Li J; Regulus Therapeutics, San Diego, CA, USA., Kaimal V; Regulus Therapeutics, San Diego, CA, USA., Karmali P; Regulus Therapeutics, San Diego, CA, USA., Felsher DW; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Publikováno v: Oncotarget [Oncotarget] 2017 Nov 09; Vol. 9 (5), pp. 5517-5528. Date of Electronic Publication: 2017 Nov 09 (Print Publication: 2018).